Apraglutide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Apraglutide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Apraglutide Today - Breaking & Trending Today

Ironwood's apraglutide wins in short bowel but CIC questioned

Positive phase III data from Ironwood Pharmaceuticals Inc. with once-weekly glucagon-like peptide-2 analogue apraglutide failed to impress Wall Street, and shares of the Boston-based firm (NASDAQ:IRWD) closed Feb. 29 at $9.43, down $5.69, or 37.6%. The experiment called Stars tested apraglutide to reduce parenteral support in adults with short bowel syndrome with intestinal failure. Rare and severe, the condition affects about 18,000 adults in the U.S., Europe and Japan. Based on the latest data, Ironwood plans to submit an NDA to the U.S. FDA and other regulatory filings. ....

United States , Ironwood Pharmaceuticals Inc , Ironwood Pharmaceuticals , Wall Street , Ironwood Pharmaceuticals Inc , Short Bowel Syndrome , Glucagon Like Peptide 2 Analogue , Glp 2 , Colon In Continuity ,

Apraglutide Reduces Parenteral Support Dependency in Patients with SBS-IF, CIC

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support. ....

Linkedin Tim Vanuytsel , Tim Vanuytsel , Ironwood Pharmaceuticals Presents Positive Final Data , Transplantation Center , Ironwood Pharmaceuticals , United European Gastroenterology Week , Leuven Intestinal Failure , Short Bowel Syndrome , Intestinal Failure , United European Gastroenterology , Vectivbio Reports Positive Interim Clinical Data , Investigating Apraglutide , Intestinal Failure Patients , Balance Study , Patients With , Stars Nutrition , Phase 2 , Parenteral Support , Sbs If , Colon In Continuity , Glp 2 ,

Ironwood Places $1B Bet on Biotech That Could Bring Its Next Blockbuster GI Drug

Ironwood Pharmaceuticals is paying $1 billion to acquire VectivBio, a biotech whose lead program could become a blockbuster treatment for a gastrointestinal disorder. Preliminary Phase 3 data are expected by the end of 2023. ....

Tom Mccourt , Ironwood Pharmaceuticals , North Chicago Based , Switzerland Based Vectivbio , Versant Ventures , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Ealth And Wellness , Mployee Wellness Programs , Hanghai Innovation Center ,

VectivBio Up 38% After Ironwood Agrees To Acquire The Swiss Biotech For About $1 Bln

Shares of VectivBio Holding AG (VECT), a clinical-stage biotech company, gained over 38% on Monday after the company agreed to be acquired by Ironwood Pharmaceuticals (IRWD) for about $1 billion. ....

Vectivbio Holding , Ironwood Pharmaceuticals , Short Bowel Syndrome ,

VectivBio Reports Full Year 2022 Financial Results and Provides Business Update

Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal. | April 19, 2023 ....

United States , Patrick Malloy , Asahi Kasei Pharma , Luca Santarelli , Program Of Apraglutide , Exchange Commission On , Vectivbio Holding Ag Nasdaq , Vectivbio Holding , Continued Strong Progress , Momentum Across Multiple Programs , Short Bowel Syndrome , Intestinal Failure , Complete Enrollment , Acute Graft Versus Host Disease , Runway Extends More , Beyond Anticipated Release , Host Call Today , Chief Executive Officer , Asahi Kasei , Graft Versus Host Disease , Inherited Metabolic Diseases , Kreos Capital , Partnering Agreement , Acute Graft Versus Disease , Annual General Meeting , Looking Statements ,